Organon & Co., a healthcare company based in Jersey City, NJ, is facing a securities class action lawsuit filed on behalf of investors who acquired the company's securities between October 31, 2024, and April 30, 2025. The lawsuit is in response to an unexpected change in the company's dividend payout policy following its acquisition of Dermavant for $1.2 billion. Despite assurances from Organon that the dividend would remain its top capital allocation priority, the company announced a reduction in its dividend from $0.28 to $0.02 per share on May 1, 2025, to focus on reducing debt. This news led to a significant decline in Organon's stock price, dropping approximately 27% to $9.45 per share. Investors who purchased Organon securities during the specified period have until July 22, 2025, to seek appointment as a lead plaintiff representative in the case. The litigation is being handled by Berger Montague PC, a firm known for its expertise in securities class action lawsuits.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.